Also trades as: 0R3M.L (LSE) · $vol 0M
VVY.AS AMS
Vivoryon Therapeutics N.V.
1W: -0.9%
1M: -2.6%
3M: -6.0%
YTD: -23.6%
1Y: -34.9%
3Y: -90.3%
5Y: -94.0%
€1.08 ($1.21)
-0.02 (-1.82%)
Weekly Expected Move ±2.5%
€1
€1
€1
€1
€1
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$0
+100.0% ▲
Gross Profit
-$147K
+95.3% ▲
Operating Income
-$21M
+27.3% ▲
Net Income
-$21M
+27.4% ▲
EPS (Diluted)
$-0.79
+29.5% ▲
EBITDA
-$20M
+28.3% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $11M | $0 | -$4M | $0 |
| YoY Growth | +0.0% | +0.0% | -100.0% | +0.0% | +100.0% |
| Cost of Revenue | $146K | $2M | $161K | -$525K | $147K |
| Gross Profit | -$146K | $9M | -$161K | -$3M | -$147K |
| Gross Margin | — | 83.9% | — | 85.5% | — |
| R&D Expenses | $13M | $17M | $20M | $18M | $14M |
| SG&A Expenses | $3M | $4M | $9M | $3M | $7M |
| Operating Expenses | $16M | $22M | $29M | $26M | $21M |
| Operating Income | -$16M | -$13M | -$29M | -$29M | -$21M |
| Operating Margin | — | -119.0% | — | 796.6% | — |
| Interest Expense | $23K | $24K | $24K | $56K | $86K |
| Income Before Tax | -$17M | -$12M | -$28M | -$29M | -$21M |
| Tax Expense | $0 | $432K | -$199K | -$234K | $0 |
| Net Income | -$17M | -$13M | -$28M | -$28M | -$21M |
| Net Margin | — | -117.6% | — | 782.9% | — |
| EPS (Diluted) | $-0.83 | $-0.63 | $-1.28 | $-1.12 | $-0.79 |
| EBITDA | -$16M | -$12M | -$28M | -$28M | -$20M |
| Shares Outstanding | 20M | 20M | 22M | 25M | 26M |